论文部分内容阅读
目的 :探讨乳腺癌雌、孕激素受体和DNA倍体表达的临床意义。方法 :采用高敏感的SP免疫组化法检测雌、孕激素受体和采用流式细胞检测DNA倍体在乳腺癌中的表达。结果 :143例乳腺癌中ER(+) /PR(+)者 78例 ,ER(+) /PR(- ) 18例 ,ER(- ) /PR(+) 12例 ,ER(- ) /PR(- ) 35例 ,ER(+)者 96例 ,占 6 7 1% ,PR(+)者 90例 ,占 6 2 9%。ER表达状况与年龄、肿瘤大小、淋巴结转移无关 (P >0 0 5) ,ER(+)者预后较好 ,3年生存率为 93 75% ,ER(- )者仅 53 2 % ,两者显著差别P <0 0 5,56例乳腺癌中 ,二倍体 2 2例 ,四倍体 9例 ,异倍体 2 5例 ,DNA倍体与年龄、肿瘤大小、淋巴结转移无关 ,(P >0 0 5) ,而二、四倍体肿瘤预后较好 ,3年生存率分别为 95 5%和 88 7% ,5年生存率分别为 90 2 %和77 8% ,异倍体预后较差 ,3年生存率仅 6 0 % ,5年生存率仅 56 %。结论 :ER和DNA倍体表达和预后密切相关 (P >0 0 5) ,可作为判断预后的指标。
Objective : To explore the clinical significance of estrogen and progesterone receptors and DNA ploidy in breast cancer. METHODS: High-sensitivity SP immunohistochemistry was used to detect the estrogen and progesterone receptors and flow cytometry was used to detect the expression of DNA ploidy in breast cancer. Results: Of 143 cases of breast cancer, 78 were ER(+)/PR(+), 18 were ER(+)/PR(-), 12 were ER(-)/PR(+), and ER(-)/PR. (-) 35 cases, ER (+) 96 cases, accounting for 67.1%, PR (+) 90 cases, accounting for 62.9%. The ER expression status was not related to age, tumor size, and lymph node metastasis (P > 0.05). The ER (+) patients had a better prognosis. The 3-year survival rate was 93 75%, and the ER (-) was only 53 2%. Significant difference P 0 05, 56 cases of breast cancer, diploid 22 cases, 9 cases of tetraploid, aneuploid 25 cases, DNA ploidy and age, tumor size, lymph node metastasis has nothing to do (P > 0 0 5) , and the prognosis of diploid and tetraploid tumors is good. The 3-year survival rates are 95 5% and 88 7%, respectively. The 5-year survival rates are 90 2 % and 77 8%, respectively. The prognosis of heteroploids is poor. The 3-year survival rate was only 60%, and the 5-year survival rate was only 56%. Conclusion : The expression of ER and DNA ploidy is closely related to prognosis (P > 0 05), which can be used as an indicator of prognosis.